Deze website maakt gebruik van cookies. We gebruiken cookies om instellingen te onthouden en je bezoek soepeler te laten verlopen. Daarnaast gebruiken we ook cookies voor de verbetering van de website en het verzamelen en analyseren van statistieken. Lees meer over cookies

Home
Rob Pieters

Rob Pieters

Kinderoncoloog

Pieters groep

Telefoon 088-9728585

E-mail R.Pieters@prinsesmaximacentrum.nl

Implementation of paediatric precision oncology into clinical practice
- nov. 2022
- Karin P.S., Langenberg, et al
- European Journal of Cancer
Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?
- sep. 2022
- Inge M., van der Sluis, et al
- British Journal of Haematology
MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus
- jul. 2022
- Kirsten, Canté-Barrett, et al
- JCI Insight
Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort
- mei 2022
- , et al
- Cancer investigation
Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia
- apr. 2022
- Linde, Dekker, et al
- Blood advances

Bekijk alle publicaties

Rob Pieters

Publicaties

Implementation of paediatric precision oncology into clinical practice

Is asparaginase encapsulated in erythrocytes effective as second-line treatment in acute lymphoblastic leukaemia?

MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus

Late Mortality in Childhood Cancer Survivors according to Pediatric Cancer Diagnosis and Treatment Era in the Dutch LATER Cohort

Fludarabine exposure predicts outcome after CD19 CAR T-cell therapy in children and young adults with acute leukemia